DNMT3A and acute myeloid leukemia: Besides genetic subtyping, AML can be characterized by shared signaling pathways and aberrant immunophenotypes such as co‐expression of CD7, CD56 (Chang et al, 2004), or a CD34lowGPR56high profile, the latter of which we associated with co‐mutations in NPM1, DNMT3A, and FLT3‐ITD (Garg et al, 2019), and high LSC frequency (Pabst et al, 2016).